· The animal health division of Bionaturis Group has signed a license agreement for the supply and distribution of non-prescription products for livestock with minimum annual orders worth of € 4.77 million

· The products subject of the contract are intended to lead to a more rational use of antibiotics in livestock

· The signing of this contract joins the uptrend of significant organic growth that every divisions of the group is performing

Jerez de la Frontera, November 16, 2017.


Bionaturis Group has reported that its animal health division has signed a license agreement for the exclusive registration and commercialization of non-prescription products for food production animals (FPAs) with an international client of regional scope. Under the license agreement, Bionaturis will supply the products and technical assistance, while the client will be in charge of importing, distributing and selling them, as well as obtaining the marketing authorization, whose ownership will be shared. The supply agreement has an initial term of three years with automatic renewal of one-year periods and a minimum annual order commitment of €4.77 million euros, once the marketing authorization has been obtained, estimated for the second quarter of 2018.

The products subject of the contract are intended to lead to a more rational use of antibiotics in livestock farms, one of the cornerstones of the One Health concept “one world, one health”, that summarizes an idea that had been known for more than a century; that human health and animal health are interdependent and bound to the health of the ecosystems in which they exist. According to the OIE – World Organization for Animal Health, 60% of known human infectious diseases are zoonotic (domestic or wild animals), as well as 75% of emerging human diseases have animal origin.

By a B2B business model, the animal health division of Bionaturis has positioned itself as a reference partner of the One Health concept, bringing to the market premium veterinary products, both prescription and non-prescription, for food production animals (FPAs) and pets (CAPs). This supply contract of non-prescription products for FPAs joins the uptrend of high organic growth performed by the different divisions of Bionaturis group, which, according to the last financial statements, expects a FY-2017 closing with net sales growth exceeding 60% YoY an at least +100% EBITDA YoY.

The One Health concept, encompassing strategic lines of the animal health division of Bionaturis Group, such as the development of new products and tools for the prevention and treatment of animal diseases, is considered by WHO (World Health Organization) as a key foundation for the fight against the growing phenomenon of microbial resistant -super bugs-.

According to CDC (US Center for Disease Control and Prevention), only in USA 2 million people are affected by super bugs every year, causing at least 23,000 deaths.

About Bionaturis Group

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. The biotech group is listed, trading with the code BNT.

For further information link here (only spanish)